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Abstract: Phantom-limb pain (PLP) belongs among difficult-to-treat chronic pain syndromes. 
Treatment options for PLP are to a large degree implicated by the level of understanding the 
mechanisms and nature of PLP. Research and clinical findings acknowledge the neuropathic 
nature of PLP and also suggest that both peripheral as well as central mechanisms, including 
neuroplastic changes in central nervous system, can contribute to PLP. Neuroimaging studies 
in PLP have indicated a relation between PLP and the neuroplastic changes. Further, it has 
been shown that the pathological neuroplastic changes could be reverted, and there is a 
parallel between an improvement (reversal) of the neuroplastic changes in PLP and pain relief. 
These findings facilitated explorations of novel neuromodulatory treatment strategies, adding 
to the variety of treatment approaches in PLP. Overall, available treatment options in PLP 
include pharmacological treatment, supportive non-pharmacological non-invasive strategies 
(eg, neuromodulation using transcranial magnetic stimulation, visual feedback therapy, or motor 
imagery; peripheral transcutaneous electrical nerve stimulation, physical therapy, reflexology, 
or various psychotherapeutic approaches), and invasive treatment strategies (eg, surgical 
destructive procedures, nerve blocks, or invasive neuromodulation using deep brain stimulation, 
motor cortex stimulation, or spinal cord stimulation). Venues of further development in PLP 
management include a technological and methodological improvement of existing treatment 
methods, an implementation of new techniques and products, and a development of new treatment 
approaches.
Keywords: phantom-limb pain (PLP), neuropathic pain, non-invasive treatment, invasive 
treatment, neuromodulation
Introduction
It is estimated that more than 80% of patients with partial or total loss of a limb develop 
chronic phantom-limb pain (PLP), ie, pain that seems to be located in the missing limb.1 
For the purposes of clinical assessment and treatment, it is important to differentiate 
PLP from other amputation-related phenomena, such as stump-pain, (ie, pain in the 
remaining part of the limb),2 non-painful phantom-limb sensation, or telescoping, 
ie, sensation when the distal part of the phantom is gradually felt to approach the residual 
limb and may even be experienced within the stump.3 Risks factors for PLP4–8 include 
gender (PLP being more common in women), upper extremity amputation,   presence of 
pre-amputation pain, residual pain in remaining limb, or time after amputation (there 
are reports of a two-peak period of onset, the first within a month after amputation 
and the second after 1 year).8 Further, stress, anxiety, depression, and other emotional 
triggers also highly likely contribute to PLP.7 Recommended preventive measures 
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include using preemptive and postoperative perineural or 
epidural local anesthetics, intraoperative precautions related 
to protection of the peripheral nerves, and importance of 
early rehabilitation.9,10
Treatment options for PLP are, to a large degree, 
implicated by the level of understanding the mechanisms 
and nature of PLP. In a historical perspective, PLP had 
been considered mostly of psychological origin, with the 
prevalent belief that PLP was generated “in the patient’s 
head.” However, the development of advanced diagnostic 
methods, recently including neuroimaging, has facilitated 
explorations of changes in peripheral and central neural 
networks after amputation and their putative contribution 
to the development of PLP.11–13 The findings acknowledged 
the neuropathic nature of PLP and also suggested that both 
peripheral, as well as central mechanisms, including neu-
roplastic changes in central nervous system, can contribute 
to PLP.14,15 In periphery, axotomized afferent neurons may 
develop retrograde degeneration and shrinking that primar-
ily involves unmyelinated neurons, and local changes at the 
site of the remaining nerve endings may contribute to the 
development of enhanced sensitivity of the afferent fibers.16 
Further, a sprouting of injured axon can lead to formation 
of neuromas in the residual limb. Neuromas show abnormal 
sensitivity to mechanical and chemical stimuli and can be 
a source of abnormal ectopic discharges.16,17 Besides neuro-
mas, dorsal root ganglions have also been shown to generate 
the discharge of ectopic activity,18 substantially increasing 
the overall barrage of abnormal afferent input to the spinal 
cord and upper centers, such as the brainstem, thalamus, or 
cortex. Further, post-amputation changes at the level of the 
spinal cord include formation of new neural connections 
between the axonal sprouts from the proximal part of the 
amputated nerve and spinal cord neurons, which contributes 
to sensitization of pain-transmission neurons. The sensitiza-
tion may manifest itself as mechanical hyperalgesia and an 
expansion of peripheral receptive fields,19 and is linked to 
an increase of activity on NMDA receptors mediated for 
example by substance P, neurokinins, and tachykinins at 
the dorsal horns of the spinal cord.20 There also may be a 
reduction in the local intersegmental inhibitory mechanisms, 
resulting in spinal disinhibition and enhanced nociceptive 
input to the supraspinal centers. Interestingly, a pathologi-
cal change of the afferent input (whether it is an increase 
or decrease) represents a significant source of neural plas-
ticity, ie, dynamic changes in the function of neurons and 
neural networks in the central nervous system, including 
both spinal and cerebral parts of the Pain Matrix, the pain 
processing network.18,21 Neuroplastic alterations at the level 
of the brain include changes in neuronal excitability, changes 
in the somatotopic organization in the cortical and subcorti-
cal areas (eg, in the somatosensory and motor cortices or in 
thalamus), and structural changes (thickening or thinning) of 
neuronal layers. Indeed, neuroimaging studies in PLP have 
shown presence of such neuroplastic changes in amputees 
and the relation to the presence of PLP.11–13,22–25 Further, it 
has been shown that the pathological neuroplastic changes 
can be reverted and that an improvement (reversal) of the 
neuroplastic changes in PLP patients was paralleled by pain 
relief.13 These findings facilitated explorations of novel 
neuromodulatory treatment strategies, such as transcranial 
magnetic stimulation (TMS) or motor imagery, adding to the 
variety of treatment approaches in PLP.
Overall, treatment options in PLP include pharmacologi-
cal treatment, supportive non-pharmacological non-invasive 
strategies, and invasive treatments.
Pharmacological treatment
The pharmacological armamentarium is vast,26–49 (Table 1), 
but efficacy of most of the drugs utilized to treat PLP have 
not been determined from PLP controlled trials, but rather 
extrapolated from positive results obtained on a variety of 
other neuropathic pain syndromes (eg, painful polyneuropa-
thy [PPN] or post-herpetic neuralgia [PHN]).
Acetaminophen and nonsteroidal  
anti-inflammatory drugs (NSAIDs)
A cross-sectional study found acetaminophen and NSAIDs 
to be the most common medications used in PLP.4 This 
widely-used over-the-counter medication has relatively 
little anti-inflammatory activity as compared to NSAIDs. 
However, acetaminophen and other NSAIDs all act by the 
same mechanism (inhibition of prostaglandin synthesis) and 
all show varying levels of analgesic, anti-inflammatory, anti-
pyretic, and antiplatelet actions, and decrease the nociception 
at peripheral and central level.28
Antidepressants
Antidepressants have been utilized for the management of 
neuropathic pain since the eighties after work by Mitchel 
Max showed analgesic effect by amitriptilyne independent 
of improvement of depression. Since then many drugs have 
been added to the list (Table 1), with different degrees of 
success.26,29,30
Tricyclics are on top of the list for their efficacy for the 
management of neuropathic pain syndromes, but the results 
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Table 1 Level of evidencea for the drugs utilized to treat phantom-limb pain and other neuropathic-pain conditions
Drug Neuropathic-pain conditions
PLP PPN PHN TN HIV CP
Acetaminophen CrS/P
NSAIDs CrS/P
Antidepressants tricyclics
  Amitriptyline CT/P/N CT/Pb CT/Pb CT/N CTb
  Desipramine CT/Pb CT/Pb b
  Imipramine CT/Pb, CT/Pb b
  Nortriptyline CT/Pb CT/Pb b
  Clomipramine CT/Pb CT/Pb
  Trazadone CT/P
  Maprotiline CT/Pb CT/Pb b
Tetracyclics
  Mirtazapine CS
SSRIs
  Escitalopram CT/P
  Fluoxetine CT/P
  Paroxetine CT/P
  Sertraline OLT/P
Bupropion CT/P CT/P
SNRIs
  Duloxetine CR CT/Pb
  Venlafaxine ER CT/N CT/Pb CT/P
  Milnacipran CR
Anticonvulsants calcium  
channel alpha 2 delta ligands
  Gabapentin CT/P CT/P/Nb CT/Pb CR CT/N CT/Pb
  Pregabalin CT/P CT/Pb CT/P CT/N CT/Pb
Carbamazepine CT/P CT/Pb
Lamotrigine CT/P/N CT/P/N
Oxcarbamazepine CT/Pb
Phenytoin CT/P/N
Topiramate CT/P/N
Valproate CT/P/N CT/P CT/N
Sodium channel blockers
  Bupivacaine (inject) CT/P
  Lidocaine
    Infusion CT/N CT/P
    Patches CT/P
  Mexiletine CT/P/N CT/N CT/N
NMDA receptor antagonists
  Memantine CR/P/N CT/P/N CT/N
  Ketaminec CT/N
  Dextromethorphan CT/P CT/N
NMDA+Potassium channel blocker  
Flupirtine (plus opioids)
CR
Opioids
  Morphine CT/P CT/P CT/P
  Methadone CS
  Buprenorphined CR/P
  Oxycodone CR/P CT/P CT/P
  Levorphanol CT(M)
  Tramadol CT/P CT/P CT/P
Muscle relaxants
  Baclofen CRd CT/P
  Benzodiazepines
    Clonazepam CS
    Diazepam CT/P
(Continued)
submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
41
Phantom-limb painJournal of Pain Research 2012:5
for the management of PLP are mixed. Due to the availability 
of newer agents with similar efficacy and better profile of side 
effects the tricyclics have been less utilized in the last few 
years. The anticholinergic effect presented by these drugs is 
responsible for the major side effects including sedation, con-
stipation, urinary retention, and electrical conduction changes 
that made them potentially problematic in the elderly. 
Sometimes the side effects can help to manage comorbidi-
ties and a night dose of amitriptyline might be preferable 
for patients with insomnia. The serotonin-norepinephrine 
reuptake inhibitors (SNRIs) are antidepressants that block 
the reuptake of serotonin and norepinephrine (eg, duloxetine) 
and although they have become popular due to a better pro-
file of side effects and similar good efficacy for neuropathic 
pain, migraines, and fibromyalgia, the level of evidence for 
the management of PLP is low (Table 1). Milnacipran, in 
the United States, has been approved for the management 
of fibromyalgia, but although the level of evidence to treat 
PLP is low, there are studies that show benefit in neuropathic 
pain.31 Agents with a preferentially dopaminergic mechanism 
of action like bupropion have also been shown to be benefi-
cial for the management of neuropathic pain. The selective 
serotonin reuptake inhibitors (SSRIs) are considered to be 
less effective but there are positive controlled trials in PPN 
for escitalopram, fluoxetine, and paroxetine (Table 1).26
Anticonvulsants
Some anticonvulsants, like gabapentin and pregabalin, have 
been shown to be efficacious for the treatment of PLP in 
controlled trials.26,32,33 The list grows when the evidence of 
efficacy is looked at on other types of neuropathic pain like 
painful peripheral neuropathy and post-herpetic neuralgia and 
includes gabapentin, pregabalin, carbamazepine, lamotrigine, 
phenytoin, topiramate, and valproate (Table 1). Pain with 
neuralgic characteristics that can occur at the level of the 
stump, can be successfully treated with the older agents like 
carbamazepine or the newer oxcarbazepine.
Sodium channel blockers
Sodium channel blockers can be administered orally, intra-
venously, epidurally, or intrathecally. The evidence that 
supports its use varies with the agent and the formulation. 
The only controlled trial that supports its use for PLP is with 
injectable bupivacaine. A study with lidocaine infusion was 
negative for PLP and another positive for PPN, while there 
are no positive trials for the oral formulation mexiletine 
(Table 1).29
NMDA receptor antagonists
Intravenous infusion of ketamine, an NMDA receptor 
antagonist, has been shown to be beneficial for PLP but other 
agents of this family have not been consistently shown to 
be efficacious. More recently it has been utilized to manage 
pain that does not respond to other agents as a single intra-
venous infusion or repetitive infusions as outpatient. Many 
clinicians treat patients that experience at least 50% pain 
reduction with the infusion, with oral ketamine that can be 
compounded.26 The long term use is in many occasions not 
possible due to side effects. There are mixed case reports with 
memantine, another NMDA antagonist that was developed 
for the management of dementia in Alzheimer’s disease, for 
PLP and positive and negative control trials for other forms 
of neuropathic pain. There are positive control trials with 
dextromethorphan for PPN and a negative trial for PHN.
Opioids
Morphine has been shown to be beneficial for the manage-
ment of PLP in a controlled trial and there is case series 
showing analgesia with methadone and a case report with 
buprenorphine reporting analgesia.29,38 In addition morphine, 
Table 1 (Continued)
Drug Neuropathic-pain conditions
PLP PPN PHN TN HIV CP
    Alprazolam OLT
Corticosteroids
    Prednisone CS
    Dexamethasone CS
Capsaicin CT/P/N CT/P CT/N
Notes: In bold characters, reports and studies specifically designed to test drugs on PLP. aOnly highest level of evidence for each drug and condition reported; bfirst-line 
drugs according to EFNS guidelines; cintravenous infusion; dintrathecal analgesia.
Abbreviations: CrS, cross-sectional study; CR, case report/case series; CT,  controlled trial; OLT, open label trial; M, mixed patient population; P, positive clinical trial;   
N, negative clinical trial; P/N, mixed clinical trial results; PLP, phantom limb pain; PPN, painful polyneuropathy; PHN, post-herpetic neuralgia; TN, trigeminal neuralgia; 
CP, central pain (post-stoke and spinal cord injury); NSAIDs, nonsteroidal anti-inflammatory drugs; SSRIs, selective serotonin reuptake inhibitors; SNRIs, serotonin-
norepinephrine reuptake inhibitors; NMDA, N-Methyl-D-Aspartate.
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oxycodone, levorphanol, and methadone are efficacious for 
the management of other forms of neuropathic pain including 
PPN and PHN. The long term use of these drugs has been 
questioned due to the scarce evidence of long term benefits 
including function. Concerns about addiction, diversion, 
and side effects including decrease in testosterone level 
have also been raised. Despite this, the use of opioids for the 
management of neuropathic pain has been supported in sev-
eral guidelines including the American Pain Society (APS) 
and the American Academy of Pain Medicine (AAPM). 
Methadone has received a differential treatment due to the 
additional concern about cardiac toxicity and the Canadian 
guidelines place it at a lower step than the other opioids.
Tramadol
There are positive clinical trials with tramadol supporting its 
use for the management of PLP and other forms of neuro-
pathic pain including PPN and PHN.29 Tramadol is an agent 
with a mixed mechanism of action that includes low affinity 
for the mu opioid receptors and the ability to blockade the 
reuptake of norepinerpine and serotonin. It can also produce 
physical dependency but it is Schedule 3 and this is one of 
the reasons why it is popular among prescribers.
Others
There are other drugs that have been utilized with variable 
degree of success, including muscle relaxants like baclofen, 
the centrally acting benzodiazepines, and the corticosteroids. 
There is a case report for baclofen in PLP that reports ben-
efit, a positive controlled trial in PHN, a positive controlled 
trial for diazepam, and an open label trial for alprazolam for 
the management of PPN. There are case series that report 
benefit with corticosteroids like prednisone dexamethasone 
for PPN. Capsaicin has been utilized for neuropathic pain 
with variable success for many years, which has not been 
very popular due to the pain that occurs after its   application. 
There is a new formulation in a patch form that seems to 
be promising, although there is no data available yet for 
PLP (Table 1).
In summary, there is a limited number of control stud-
ies done specifically to assess drug efficacy in PLP.26 The 
ones showing significant beneficial effect include trials with 
amitriptyline,30 gabapentin,32 tramadol,40 and morphine.33 
There are also some case reports/series with mirtazapine,41 
duloxetine,33 milnacipran,31 memantine,34,35 baclofen,36 
buprenorphine,37 and methadone,38 that suggest beneficial 
effects on PLP. The selection of the agent should be based 
on the current understanding of PLP as a neuropathic type 
of condition. Hence, in addition to drugs that show efficacy in 
PLP, other drugs with efficacy in other types of neuropathic 
pain could be prescribed.38 However, the drug selection 
should take into consideration the clinical presentation of 
the PLP syndrome. PLP is continuous, intense, sometimes 
burning and for that reason a drug with efficacy in PPN or 
PHN may be chosen. Further, as a neuralgic type of pain 
may be present in PLP (possibly a result of a neuroma 
formation in the stump), drugs efficacious in neuralgic type 
of pain, like carbamazepine or oxcarbamazepine, can be 
added to the regimen. A trial in every patient should include 
appropriate titration of the drug up to levels where efficacy 
has been shown in other neuropathic conditions, for at least 
4–6 weeks. Thus, completion of an appropriate trial usually 
takes 1–2 months.39
It has been proposed that the administration of analgesic 
and anesthetics prior to a surgical intervention9,42 and intra-
operative precautions with the handling of peripheral nerves 
and not to ligate with sutures, could prevent the development 
of central sensitization due to impulses generated at the level 
of the amputation, however the results have been mixed. 
Epidural analgesia, ropivacaine, and patient controlled anal-
gesia during the perioperative period have shown to decrease 
PLP, but ketamine and ketamine plus bupivacaine showed 
conflicting results.4,44,45
As PLP is often of severe intensity, causing a long-lasting 
and debilitating decrease of quality of life in many ampu-
tees,48 pharmacological treatment itself in many patients 
does not provide sufficient pain relief. Therefore, supportive 
treatments may enhance the treatment regimen.
Supportive non-invasive treatment 
approaches
Non-invasive neuromodulation
Several approaches are available within non-invasive neu-
romodulation in PLP, for example repetitive transcranial 
magnetic stimulation (rTMS), visual feedback (mirror-box 
therapy), or motor imagery.
Transcranial magnetic stimulation (TMS)
TMS exerts its effects on brain structures via electrical cur-
rents induced by a powerful magnetic field delivered with a 
magnetic coil over the scalp.49 It can be delivered as a single 
pulse or as sets of pulses (rTMS). Several studies have shown 
that a single session of rTMS can transiently relieve pain 
in some patients with chronic neuropathic pain,50–54 and a 
multiple application on several consecutive days can lead to 
prolongation of the effects.55,56 However, results from rTMS 
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treatment specifically in patients with PLP are anecdotal, 
based on case-reports but not sham-controlled trials, and 
therefore not conclusive.55–57 Although the application of 
rTMS in PLP patients resulted in pain relief,55–57 short-term 
durability of the effects is a significant issue limiting clinical 
use of this treatment.
Visual feedback therapy and motor imagery
Both the visual feedback therapy (mirror-box therapy) 
and motor imagery are based on behaviorally relevant 
sensory-motor stimulation of the stump.58–62 A rationale 
of this approach arises from the existence of maladaptive 
neuroplastic changes underlying PLP, specifically cortical 
reorganization in the somatosensory and motor cortices, 
a relation between the cortical reorganization and the 
occurrence of PLP, and beneficial effects of cortical nor-
malization on PLP.
The treatment using visual feedback emerged from the 
observation that looking at the reflection of an intact limb 
in a mirror box can induce sensations of movement in the 
phantom limb.59–65 Motor imagery is based on percepts 
or sensations generated internally by the brain, a mental 
representation of an actual sensation or movement.58 
Physiological studies have shown that both the mirror-
box therapy and the motor imagery resulted in increased 
excitability of the corticospinal pathways.64 This at least 
partially depends on the so-called mirror-neuron system61 
which includes neurons that are active not only during the 
execution of the task itself but also during the observation 
of the task. This finding provides support for the idea that 
imagined movements share the same cortical pathways as 
executed motor tasks. Further, it has been shown that visual 
feedback actually dominates somatosensory feedback and 
sensory experiences can be evoked by visual information 
alone, and it has been shown that the visual system enhances 
tactile sensitivity.61,65
Both the mirror therapy and the motor imagery can be 
very beneficial in PLP patients.58,60,62,63,66–68 As an example, 
a controlled neuroimaging study of motor imagery in PLP58 
showed evidence of cortical reorganization of motor and 
somatosensory cortices and its correlation with patients’ 
pain scores prior to the motor imagery training. The training 
resulted in a significant decrease of intensity and unpleasant-
ness of pain which correlated with reduction (improvement) 
of cortical reorganization.
Overall, the mirror-box therapy and motor imagery 
are safe and non-expensive additions to the PLP treatment 
options.
Other supportive non-invasive therapies
There is preliminary evidence that PLP patients may ben-
efit from other non-invasive supportive treatments, such as 
physical therapy including the stump and phantom limb, 
reflexology or hypnosis,69,70 or peripheral transcutaneous 
electrical nerve stimulation of the affected limb.71 Although 
there are multiple reports of transcutaneous electrical nerve 
stimulation use in PLP, a recent systematic review72 revealed 
lack of evidence from randomized controlled trials on which 
effectiveness of transcutaneous electrical nerve stimulation 
for PLP could be judged.
Further, a use of myoelectric prosthesis may improve 
PLP.73,74 Research of stimulation-induced neural plasticity 
indicate that extensive behaviorally relevant stimulation of 
the affected part of the body leads to an expansion of its 
representation zone, and an intensive use of a myoelectric 
prosthesis has been shown to be positively linked to decreased 
PLP as well as decreased degree of cortical reorganization.75 
Another venue of non-invasive support to PLP patients 
includes various psychotherapeutic approaches.76
Invasive treatment strategies
Surgical destructive interventions  
and nerve blocks
Because of a high rate of refractory chronic pain among PLP 
patients with failed non-invasive treatments, all kinds of 
invasive procedures were performed in the history of those 
cases.77–93 Destructive procedures like thermal nerve root 
destruction, rhizotomy, spinal ganglionectomy, and also dorsal 
root entry zone lesion have been performed.83–93 As per their 
nature, most of these procedures led to unrestorable damage of 
nervous tissue and functions. Initial results with high rates of 
pain relief were accompanied with a high rate of complications 
and followed by a high rate of recurrent pain and therefore 
yielding disappointing long term results after several months. 
Nowadays, the indication for destructive procedures is limited 
only to a few diagnoses for severe, refractory pain patients 
with short life expectancy. The dorsal root entry zone lesion 
is the only destructive procedure for selected patients with 
deafferentation pain and brachial plexus avulsion or cervical 
nerve root injury. In total, numbers of destructive procedures 
are decreasing year by year.
Non-destructive interventions such as nerve blocks have 
also been used in the PLP treatment. For example, intersca-
lene blocks or stellate ganglion blocks for upper extremity 
PLP, or lumbar sympathetic blocks for lower extremity 
PLP can lead to decrease of PLP.95 These blocks are often   
combined with physical therapy.
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Invasive neuromodulation
Invasive neuromodulation is considered the last-resort treat-
ment for patients who failed various trials of non-invasive 
treatments. On contrary to surgical destructive procedures, 
neuromodulatory techniques are PLP-mechanisms-driven, 
specifically addressing maladaptive central neuroplas-
tic changes in the Pain Matrix (brain pain-processing 
networks).
Deep brain stimulation (DBS)
DBS is an electrical stimulation performed after stereotactic 
implantation of thin stick leads into subcortical areas such 
as the thalamus or basal ganglia. In the early 1950s, the first 
clinicians used thalamic stimulation to treat chronic pain 
patients.78–83 Since these first clinical applications a lot 
of case series, retrospective patient samples, and reviews 
were published.81,82,88–91,93,96,97 A recent review98 lists a total 
of 600 patients with DBS due to different chronic pain 
  syndromes. Evidence up to date suggests that the significance 
of DBS for PLP is controversial. However, some patients 
clearly benefit from DBS, experiencing long term pain 
relief .25% and improved quality of life.97
Motor cortex stimulation (MCS)
MCS (Figure 1) is an electrical stimulation of the precen-
tral gyrus using epidural surgical leads and subthreshold 
stimulation.99–103
Historically, after the application of MCS in patients with 
post-stroke-pain or trigeminal neuropathic pain, also patients 
with PLP became candidates for the MCS treatment.98,104–107 
Some centers perform a direct implantation of the neuro-
stimulator in the subcutaneous tissue (infraclavicular or 
abdominal), while others perform also a postoperative test-
ing with externalized extensions of the lead and an external 
stimulation.98,106,108,109 Such a testing phase allows for a 
placebo double-blinded stimulation period, so that false posi-
tive responders can be identified.106 It has been suggested106 
that the definite implantation of neurostimulator would be 
performed only in patients with a positive effect of the real 
MCS and a pain reduction of .30%, and the subjective 
impression of pain improvement by the patient. Information 
from different centers and experts98,105,109,110 show that PLP 
is an accepted indication for MCS. PLP of the upper limb 
seems to be favorable due to the large representation on the 
convex part of the precentral gyrus, but interhemispheral lead 
implantation for the lower limb has also been reported, and 
a review of evidence98 suggests that MCS yields favorable 
results in about 53% of PLP patients.
Spinal cord stimulation (SCS)
SCS involves the placement of electrodes in the epidural 
space adjacent to the spinal area presumed to be the source 
of pain. An electric current is then applied to achieve sym-
patholytic and other neuromodulatory effects.111 Typically, 
the first phase of treatment involves the temporary placement 
of an electrical stimulator. Patients are monitored over a 
period of time to determine the pain reduction. Only patients 
positively responding to the stimulation would be consid-
ered for a permanent implantation. Clinical results indicate 
beneficial effects of SCS in PLP patients on immediate as 
well as long term outcomes,112,113 although the percentage of 
benefiting patients declined with time. For example, good 
results have been observed at 2 year follow-up in 52.4% of 
64 PLP patients, that decreased to 39% at 5 year follow-up.113 
However, given the fact that PLP is a difficult-to-treat pain 
syndrome and many PLP patients do not respond to other 
treatment strategies, SCS represents a promising treatment 
option for selected subpopulation of patients. Similarly to 
other invasive treatments, such as MCS or DBS, SCS is also 
reserved for patients that had not benefited from non-invasive 
treatment strategies.
Conclusions and future directions
Although some of the currently available therapies yield 
promising results, many PLP patients still remain without 
satisfactory pain relief. Therefore, continual advances in the 
PLP treatment are of high importance. It can be anticipated 
Figure 1 Lateral x-ray of the skull documenting the position of the implanted paddle 
leads. Matching of postoperative ct-scan and preoperative MRI-3D-neuronavigation 
data with inserted position of the leads over the pre- and postcentral gyrus.
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that pain management in PLP patients may in the future 
benefit from the following venues:
•	 Technological and methodological improvement of exist-
ing treatment methods.
  Improved formulations of pharmacological agents, such 
as long-acting formulations or new routes of applica-
tions, may improve pain relief and overall quality of 
life in patients with PLP. Further, as discussed in other 
sections of this article, efficacy of various neuropathic-
pain medications has not yet been established for PLP. 
  Establishing the drug efficacy specifically for PLP can 
certainly facilitate a patient-tailored selection of more-
benefiting pharmacological regimens for PLP patients.
Further, it is anticipated that an improvement of 
invasive DBS and MCS treatments will be facilitated by 
technological advances of imaging techniques, as higher 
resolution would provide more accurate information 
about the relevant brain structures. Furthermore, techno-
logical advances in the detection of pain-related electrical 
signals in the brain or at its surface would enable more 
specific and target-oriented DBS and MCS.
•	 Implementation of new methods and products within 
current PLP treatment-strategies.
  Besides the fast progress of the pharmaceutical indus-
try and implementation of new agents, also non-
  pharmacological treatment strategies in PLP may enrich 
their repertoire of available methods. For example, within 
the non-invasive neuromodulatory strategy, transcranial 
direct current stimulation114 that has recently shown 
promising clinical potential in some neuropathic pain 
syndromes, may be in the future explored in the treat-
ment of PLP. As transcranial direct current stimulation 
yielded pain relief in various patient-populations (eg, 
patients with fibromyalgia, Parkinson’s disease, pelvic 
pain, central pain due to spinal cord injuries),115–119 it can 
be anticipated that PLP patients as well may benefit from 
this method. Further, a wider implementation of the use of 
myoelectric prosthesis in clinical practice may enrich PLP 
management in the future. Behaviorally relevant stimu-
lation of the stump delivered via myoelectric prosthesis 
addresses cortical reorganization75 has been identified 
among pathological mechanisms underlying PLP.
•	 Development of new treatment approaches.
  Pain research incorporating new perspectives, such as 
genetics and epi-genetics, provides an exciting opportunity 
to enhance the insight into the mechanisms and develop-
ment of chronic pain syndromes, including PLP, and to 
provide an evidence base for the development of novel 
treatment approaches and targets. For example, recent 
studies indicate that gene CACNG2, which is expressed 
in the peripheral and central nervous system and encodes 
neuroprotein stargazin, may be implicated in the develop-
ment neuropathic pain. If confirmed by future studies, the 
gene may be of high significance for PLP. Understanding 
genetic and epigenetic factors (ie, functionally relevant 
modifications to the genome that do not involve a change 
in the nucleotide sequence) in the development of PLP may 
lead to exploration of epigenetic pharmaceuticals for this 
difficult-to-treat condition, as recently witnessed in other 
areas of medicine, for example in oncology.120
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